NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

11089	Companies
243639	Keywords
171776	Articles
131242	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 06/08/2026 at 14:30, 3 months 20 days ago

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
NanoViricides, Inc. proposes Phase II Trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus. Potential treatment for current outbreak, offering oral delivery of broad-spectrum antiviral drug

NanoViricides NV-387 Phase II Trial Antiviral Drug Ebolavirus
BRIEF

published on 05/26/2026 at 14:35, 4 months 2 days ago

NanoViricides' NV-387 Prepared for Ebola Treatment Amidst Outbreak

NanoViricides NV-387 Public Health Antiviral Drug Ebola Outbreak
BRIEF

published on 05/26/2026 at 14:35, 4 months 2 days ago

NanoViricides prépare son NV-387 pour le traitement d'Ebola en pleine épidémie.

NanoViricides NV-387 Santé Publique Médicament Antiviral Épidémie D'Ebola
PRESS RELEASE

published on 05/26/2026 at 14:30, 4 months 2 days ago

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
NanoViricides, Inc. announces potential treatment option for Ebola Bundibugyo virus strain, highlighting broad-spectrum antiviral drug candidate NV-387, superior to Remdesivir, ready for Phase II clinical trial

NanoViricides NV-387 Clinical Trial Antiviral Drug Ebola Bundibugyo
BRIEF

published on 05/19/2026 at 06:00, 4 months 10 days ago

NanoViricides Closes $2 Million Registered Direct Offering

Securities NanoViricides Investment Direct Offering Antivirals
BRIEF

published on 05/19/2026 at 06:00, 4 months 10 days ago

NanoViricides clôture une offre directe enregistrée de 2 millions de dollars

Investissement NanoViricides Titres Offre Directe Antiviraux
PRESS RELEASE

published on 05/19/2026 at 05:55, 4 months 10 days ago

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
NanoViricides, Inc. announces closing of $2M direct offering. Exclusive placement agent D. Boral Capital LLC. SEC registration effective. NV-387, a revolutionary antiviral drug granted Orphan Drug Designation

NanoViricides NV-387 Direct Offering SEC Registration D. Boral Capital LLC
BRIEF

published on 05/18/2026 at 14:35, 4 months 10 days ago

NanoViricides Highlights NV-387 as a Potential Solution for Ebola Outbreak

NV-387 Antiviral Drug Pandemic Preparedness Ebola Outbreak Bundibugyo Strain
BRIEF

published on 05/18/2026 at 14:35, 4 months 10 days ago

NanoViricides met en avant le NV-387 comme solution potentielle à l'épidémie d'Ebola

NV-387 Médicament Antiviral Préparation Aux Pandémies Épidémie D'Ebola Souche Bundibugyo
PRESS RELEASE

published on 05/18/2026 at 14:30, 4 months 10 days ago

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
NanoViricides, Inc. highlights the urgent need for a broad-spectrum antiviral drug like NV-387 amid an Ebolavirus outbreak in DR Congo and Uganda. NV-387 holds promise as it targets sulfated proteoglycans crucial for viral attachment to cells

NanoViricides NV-387 Antiviral Drug Broad-spectrum Ebolavirus Outbreak

Accesswire

Published on 09/29/2026 at 09:01, 29 minutes ago

Star Copper Advances Western Extension Drilling at Star Main
Published on 09/29/2026 at 06:45, 2 hours 45 minutes ago

Akkodis and Biolevate Partner to Accelerate AI-Powered Scientific, Regulatory and Technical Documentation in Highly Regulated Industries
Published on 09/29/2026 at 04:36, 4 hours 54 minutes ago

The Next Decade of Medical AI: How Humans and AI Collaborate - A Conversation Between Kevin Kelly and Dr. Ning Song of Diagens Tech (2526. HK)
Published on 09/29/2026 at 02:30, 7 hours ago

QNX and neueHCT Join Forces to Accelerate Global Intelligent Driving Deployment, Anchored by Major German Automaker Program Win
Published on 09/29/2026 at 00:00, 9 hours 30 minutes ago

Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial

View all ACCESSWIRE

EQS Group

Published on 09/29/2026 at 09:05, 25 minutes ago

Advanet Introduces Renesas RZ/G3L-Based Industrial Computing Product Family
Published on 09/29/2026 at 09:00, 30 minutes ago

Official List Notice
Published on 09/29/2026 at 09:00, 30 minutes ago

Removal- Gresham House Renewable Energy VCT 1 plc
Published on 09/29/2026 at 09:00, 30 minutes ago

Removal- Gresham House Renewable Energy VCT2 Plc
Published on 09/29/2026 at 09:00, 30 minutes ago

Bitcoin Group SE publishes Half-Year Report 2026: Focus on relaunch of bitcoin.de with significantly expanded product offering

Les Echos

Published on 09/29/2026 at 08:45, 45 minutes ago

Cegedim Santé réinvente l’accès à l’information médicale en déployant l’Assistant by Claude Bernard IA sur toutes ses solutions de médecine de ville
Published on 09/28/2026 at 17:54, 15 hours 36 minutes ago

Reporting on share buyback transactions carried out between September 21 and September 25, 2026
Published on 09/28/2026 at 17:54, 15 hours 36 minutes ago

Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 21 et le 25 septembre 2026
Published on 09/28/2026 at 17:45, 15 hours 45 minutes ago

Weekly share buyback
Published on 09/28/2026 at 17:45, 15 hours 45 minutes ago

Déclaration hebdomadaire de rachat d'actions

View all LES ECHOS COMFI WIRE